Two Sigma Investments LP Sells 39,173 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Two Sigma Investments LP reduced its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 78.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,915 shares of the biotechnology company's stock after selling 39,173 shares during the period. Two Sigma Investments LP's holdings in Ascendis Pharma A/S were worth $1,503,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Virtus ETF Advisers LLC increased its position in Ascendis Pharma A/S by 3.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company's stock worth $368,000 after purchasing an additional 100 shares during the last quarter. Legato Capital Management LLC increased its holdings in shares of Ascendis Pharma A/S by 7.5% during the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock valued at $264,000 after acquiring an additional 134 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in shares of Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 197 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter valued at about $28,000. Finally, Blue Trust Inc. increased its holdings in shares of Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 328 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND traded up $3.86 during trading on Thursday, hitting $177.55. 358,045 shares of the stock were exchanged, compared to its average volume of 489,823. The company has a market capitalization of $10.83 billion, a price-to-earnings ratio of -25.01 and a beta of 0.41. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $183.00. The company's fifty day simple moving average is $158.09 and its 200-day simple moving average is $145.77.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. On average, research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

ASND has been the topic of a number of analyst reports. The Goldman Sachs Group increased their price objective on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Bank of America increased their target price on Ascendis Pharma A/S from $196.00 to $201.00 and gave the company a "buy" rating in a research note on Tuesday. Wedbush increased their target price on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Royal Bank of Canada increased their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Finally, JPMorgan Chase & Co. increased their target price on Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a research note on Friday, May 2nd. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S presently has a consensus rating of "Moderate Buy" and a consensus target price of $216.73.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.